Details of the Drug

General Information of Drug (ID: DMF6Y0L)

• Drug Name: Polatuzumab vedotin

Indication

Disease Entry	ICD 11	Status	REF
Diffuse large B-cell lymphoma	2A81	Approved	[1]
Follicular lymphoma	2A80	Phase 2	[2]
Haematological malignancy	2B33.Y	Phase 2	[3]

• ATC Code:
  L01FX14: Polatuzumab vedotin
  L01FX: Other monoclonal antibodies and antibody drug conjugates
  L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  L01: ANTINEOPLASTIC AGENTS
  L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
• Drug Type: Antibody
• ADMET Property:
  Clearance: The clearance of drug is 0.9 L/day []
  Half-life: The concentration or amount of drug in body reduced by one-half in 12 days [4]
  Metabolism: The drug is metabolized via the cytochrome P450 3A4 []
  Vd: The volume of distribution (Vd) of drug is 3.15 L []
• Cross-matching ID:
  UNII: KG6VO684Z6
  DrugBank ID: DB12240
  TTD ID: D05QOL
  INTEDE ID: DR1311
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell-specific glycoprotein B29 (CD79B)	TTBN5I7	CD79B_HUMAN	Not Available	[1]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[5]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Polatuzumab vedotin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Polatuzumab vedotin and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[6]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Polatuzumab vedotin caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[7]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Polatuzumab vedotin and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[8]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Polatuzumab vedotin caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[9]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Polatuzumab vedotin caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[7]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Polatuzumab vedotin caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[7]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Polatuzumab vedotin and Siponimod.	Multiple sclerosis [8A40]	[6]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Polatuzumab vedotin and Ozanimod.	Multiple sclerosis [8A40]	[10]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Polatuzumab vedotin caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[7]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Polatuzumab vedotin caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[7]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Polatuzumab vedotin caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[11]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Polatuzumab vedotin caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[7]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Polatuzumab vedotin caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[7]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] FDA label of Polatuzumab vedotin-piiq. The 2020 official website of the U.S. Food and Drug Administration.
• [6] Cerner Multum, Inc. "Australian Product Information.".
• [7] Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
• [8] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [9] Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
• [10] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [11] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.